Navigation Links
ResMed Takes Action to Enforce Patents Against BMC and 3B
Date:6/5/2013

SAN DIEGO, June 5, 2013 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions, has filed a lawsuit in U.S. Federal Court, Southern District of California in San Diego, to stop infringement of ResMed patents.

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

ResMed filed the action against Chinese medical device manufacturer BMC Medical Co., Ltd. and its U.S. sales subsidiary, 3B Products, LLC, asserting patent infringement by:

  • The RESmart CPAP and RESmart Auto CPAP devices
  • The Willows nasal pillows patient interface and the iVolve nasal mask.
  • ResMed further filed a request to add BMC to its pending International Trade Commission (ITC) case against Taiwanese manufacturer APEX to stop the importation and sales of these products in the United States.

    The ITC case against APEX, filed March 27, 2013, also named Medical Depot, Inc., doing business as Drive Medical Design and Manufacturing, in the patent infringement case. On May 30, Drive Medical Design and Manufacturing filed papers stating that it is prepared to enter into a consent decree promising to stop importation and sales of the APEX products named in the ITC proceeding. 

    "ResMed has built its unique market differentiation by investing in superior technology and medical science-driven innovation for sleep-disordered breathing therapy," said ResMed global general counsel and chief administrative officer David Pendarvis . "We will continue to defend our proprietary technology by enforcing our patents."

    About ResMed:
    ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

    Contacts:For News MediaFor the Finance and Investor CommunityGretchen GriswoldConstance BienfaitDirector, Global Corporate CommunicationsDirector, Investor RelationsO: 858-836-6789O: 858-836-5971news@resmed.comconstance.bienfait@resmed.com


    '/>"/>
    SOURCE ResMed Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ResMed Launches SleepSeeker Online Tool to Increase Patient Engagement in Therapy for Sleep-Disordered Breathing
    2. The University of Sydney and ResMed partner to accelerate research in sleep-disordered breathing and biomedical engineering
    3. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Nine Months Ended March 31, 2013
    4. ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
    5. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
    6. ResMed Takes Action to Enforce Patents
    7. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
    8. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2012
    9. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
    10. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
    11. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/19/2017)... -- Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor ... global anti-obesity drugs market is expected to grow at a ... and CAGR of 38.7% in the second half of the forecast ... 32.8% from 2016 to 2027. The market is estimated at $1,058 ... 2027. ...
    (Date:1/19/2017)... CITY, Calif. , Jan. 19, 2017  Abaxis, ... company manufacturing point-of-care blood analysis instruments and consumables for ... conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on ... results for the third quarter fiscal year 2017 after ...
    (Date:1/19/2017)... 2017 ViewRay, Inc. (Nasdaq: VRAY) announced today that ... research in Germany , has purchased ... the University Clinic Heidelberg as part of its initiative ... program will be headed by Medical Director and Professor ... at the German Cancer Research Center (DKFZ), the Heidelberg ...
    Breaking Medicine Technology:
    (Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based out of ... show to continue the marketing and distribution of its product, The Right C. , ... percent better absorption than traditional vitamin C supplements. At the trade show, Doctor C ...
    (Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company ... bodybuilding supplements, announced it attended the January ECRM trade show in Hilton Head, SC. ... scientist who was determined to create a line of products that would elevate her ...
    (Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is ... life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater ... spent her career as an educator interacting with countless women who had little knowledge ...
    (Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
    (Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More ... to the issue of world hunger, and shares the simple and achievable answer. “The ... husband and member of the Fairview Missionary Church in Angola, Indiana where he works ...
    Breaking Medicine News(10 mins):